Peptonic Medical

The first order, with an initial value of USD 120,000, was received in October 2025, and work on product design and delivery preparations has been ongoing since then and continues to proceed according to plan. The fact that Peptonic is now approaching its first delivery represents an important milestone in the Company’s international growth strategy.

– The fact that we are now approaching the first delivery under the agreement is a significant milestone for Peptonic. It demonstrates both the international relevance of our product portfolio and our ability to build scalable growth through partnerships. The US and the other agreed markets are strategically important to us, and this is a concrete step towards our ambition to reach more women with effective, gentle and science-based products in the field of intimate self-care,” says Daniel Rudeklint, interim CEO of Peptonic Medical.

The Company’s growth strategy is based on geographical expansion, strategic partnerships and product development. By combining Peptonic’s product development and medical technology expertise with the partner’s established market presence, the conditions are created to reach more women with high-quality self-care products and contribute to increased knowledge, accessibility and the normalisation of intimate self-care.

For further information, please contact:

Daniel Rudeklint, interim CEO, Peptonic Medical AB

Email: daniel.rudeklint@peptonicmedical.se

Telephone: +46 73 158 02 73

About Peptonic Medical AB

Peptonic Medical AB (publ) is a Swedish medical technology company that develops and sells clinically proven self-care products for women’s intimate health. Under the VagiVital and Vernivia brands, the Company offers a range of effective and gentle over-the-counter products that help women understand, treat and prevent common gynaecological conditions. Peptonic’s growth strategy is based on geographical expansion, particularly in the US and Europe, and on continuously strengthening the product portfolio through in-house product development and strategic acquisitions.